Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / COM
-
Number of holders
-
123
-
Total 13F shares, excl. options
-
37,285,807
-
Shares change
-
-1,543,764
-
Total reported value, excl. options
-
$1,409,999,138
-
Value change
-
-$55,448,638
-
Put/Call ratio
-
421%
-
Number of buys
-
66
-
Number of sells
-
-50
-
Price
-
$37.82
Significant Holders of AIMMUNE THERAPEUTICS INC - COM (AIMT) as of Q4 2017
141 filings reported holding AIMT - AIMMUNE THERAPEUTICS INC - COM as of Q4 2017.
AIMMUNE THERAPEUTICS INC - COM (AIMT) has 123 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 37,285,807 shares
.
Largest 10 shareholders include Foresite Capital Management II, LLC (3,100,146 shares), BlackRock Inc. (2,743,812 shares), Vanguard Group Inc (2,586,272 shares), FMR LLC (2,570,040 shares), PRICE T ROWE ASSOCIATES INC /MD/ (2,514,167 shares), Aisling Capital LLC (2,240,000 shares), EAGLE ASSET MANAGEMENT INC (1,993,673 shares), CARILLON TOWER ADVISERS, INC. (1,555,734 shares), ALLIANCEBERNSTEIN L.P. (1,400,281 shares), and ADAGE CAPITAL PARTNERS GP, L.L.C. (1,300,000 shares).
This table shows the top 123 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.